Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Billiontoone, Inc. stock logo
BLLN
Billiontoone
$100.07
+3.4%
$115.60
$61.96
$150.44
$4.56BN/A842,120 shs902,951 shs
CorVel Corp. stock logo
CRVL
CorVel
$70.14
-1.5%
$62.73
$44.83
$93.45
$3.63B0.98184,841 shs102,330 shs
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$12.28
+1.0%
$10.99
$4.77
$12.97
$4.72B1.144.22 million shs3.62 million shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$23.94
-0.6%
$21.89
$10.28
$26.92
$1.47B1.731.54 million shs653,210 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Billiontoone, Inc. stock logo
BLLN
Billiontoone
+1.80%+3.01%-23.27%+14.46%+9,673,999,900.00%
CorVel Corp. stock logo
CRVL
CorVel
+1.54%+6.52%+18.99%+16.67%-23.11%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-2.49%-3.11%+11.56%+60.63%+119.10%
Omada Health, Inc. stock logo
OMDA
Omada Health
+0.80%+1.39%+17.29%+49.57%+12.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Billiontoone, Inc. stock logo
BLLN
Billiontoone
$100.07
+3.4%
$115.60
$61.96
$150.44
$4.56BN/A842,120 shs902,951 shs
CorVel Corp. stock logo
CRVL
CorVel
$70.14
-1.5%
$62.73
$44.83
$93.45
$3.63B0.98184,841 shs102,330 shs
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$12.28
+1.0%
$10.99
$4.77
$12.97
$4.72B1.144.22 million shs3.62 million shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$23.94
-0.6%
$21.89
$10.28
$26.92
$1.47B1.731.54 million shs653,210 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Billiontoone, Inc. stock logo
BLLN
Billiontoone
+1.80%+3.01%-23.27%+14.46%+9,673,999,900.00%
CorVel Corp. stock logo
CRVL
CorVel
+1.54%+6.52%+18.99%+16.67%-23.11%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-2.49%-3.11%+11.56%+60.63%+119.10%
Omada Health, Inc. stock logo
OMDA
Omada Health
+0.80%+1.39%+17.29%+49.57%+12.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Billiontoone, Inc. stock logo
BLLN
Billiontoone
2.50
Moderate Buy$126.7126.63% Upside
CorVel Corp. stock logo
CRVL
CorVel
2.00
HoldN/AN/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
2.73
Moderate Buy$12.380.77% Upside
Omada Health, Inc. stock logo
OMDA
Omada Health
2.71
Moderate Buy$26.5010.69% Upside

Current Analyst Ratings Breakdown

Latest OMDA, LFST, BLLN, and CRVL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
Boost Price TargetBuy$16.00 ➝ $18.00
8/14/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingOutperform
8/14/2026
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
Boost Price TargetNeutral$9.00 ➝ $13.00
8/14/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Boost Price TargetOverweight$26.00 ➝ $30.00
8/14/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Boost Price TargetMarket Outperform$27.00 ➝ $32.00
8/12/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Boost Price TargetNeutral$15.00 ➝ $25.00
8/11/2026
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
UpgradeHold (C-)Hold (C)
8/11/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
UpgradeSell (E+)Sell (D+)
8/10/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Boost Price TargetBuy$30.00 ➝ $35.00
8/7/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingOutperform$24.00
8/7/2026
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
Boost Price TargetBuy$15.00 ➝ $16.00
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Billiontoone, Inc. stock logo
BLLN
Billiontoone
$305.11M15.48$0.33 per share298.88$11.38 per share8.79
CorVel Corp. stock logo
CRVL
CorVel
$958.53M3.73$2.74 per share25.64$8.02 per share8.75
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$1.42B3.34$0.17 per share72.29$3.81 per share3.22
Omada Health, Inc. stock logo
OMDA
Omada Health
$260.21M5.63N/AN/A$4.13 per share5.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Billiontoone, Inc. stock logo
BLLN
Billiontoone
$7.45M$0.70142.9692.66N/A8.04%9.96%5.35%N/A
CorVel Corp. stock logo
CRVL
CorVel
$110.34M$2.2531.17N/AN/A11.72%29.92%17.82%11/3/2026 (Estimated)
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$9.66M$0.1394.4753.39N/A3.19%3.39%2.33%11/5/2026 (Estimated)
Omada Health, Inc. stock logo
OMDA
Omada Health
-$12.78M$0.05478.80133.00N/A1.39%2.60%1.98%N/A

Latest OMDA, LFST, BLLN, and CRVL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$0.0328$0.06+$0.0273$0.06$414.58 million$435.35 million
8/6/2026Q2 2026
Omada Health, Inc. stock logo
OMDA
Omada Health
-$0.02$0.08+$0.10$0.08$80.93 million$87.84 million
8/5/2026Q2 2026
Billiontoone, Inc. stock logo
BLLN
Billiontoone
$0.15$0.15N/A$0.15N/A$109.45 million
8/4/2026Q1 2027
CorVel Corp. stock logo
CRVL
CorVel
N/A$0.63N/A$0.63N/A$259.93 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Billiontoone, Inc. stock logo
BLLN
Billiontoone
N/AN/AN/AN/AN/A
CorVel Corp. stock logo
CRVL
CorVel
N/AN/AN/AN/AN/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
N/AN/AN/AN/AN/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Billiontoone, Inc. stock logo
BLLN
Billiontoone
0.17
11.69
11.31
CorVel Corp. stock logo
CRVL
CorVel
N/A
1.94
1.94
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
0.18
1.38
1.38
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
3.91
3.85

Institutional Ownership

CompanyInstitutional Ownership
Billiontoone, Inc. stock logo
BLLN
Billiontoone
N/A
CorVel Corp. stock logo
CRVL
CorVel
51.36%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
85.50%
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A

Insider Ownership

CompanyInsider Ownership
Billiontoone, Inc. stock logo
BLLN
Billiontoone
50.22%
CorVel Corp. stock logo
CRVL
CorVel
39.72%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
3.50%
Omada Health, Inc. stock logo
OMDA
Omada Health
6.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
Billiontoone, Inc. stock logo
BLLN
Billiontoone
62047.19 million23.49 millionN/A
CorVel Corp. stock logo
CRVL
CorVel
5,23951.01 million30.75 millionOptionable
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
10,961387.83 million374.26 millionOptionable
Omada Health, Inc. stock logo
OMDA
Omada Health
84961.22 million57.31 millionN/A

Recent News About These Companies

Omada Health (NASDAQ:OMDA) Price Target Raised to $30.00
Omada Health (NASDAQ:OMDA) Price Target Raised to $32.00
Omada Health (OMDA) Q2 2026 Earnings Call Transcript
Omada Health (NASDAQ:OMDA) CEO Sells 8,628 Shares of Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Billiontoone stock logo

Billiontoone NASDAQ:BLLN

$100.07 +3.33 (+3.44%)
Closing price 04:00 PM Eastern
Extended Trading
$99.60 -0.47 (-0.47%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule. This leap forward addresses a fundamental limitation in healthcare – the inability to detect sparse but clinically crucial disease signals in cfDNA. Our superior technology platform(1) has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine. We believe our novel smNGS platform technologies combined with our AI-enhanced integrated workflow, allows us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy, which we estimate has an annual market opportunity of over $100 billion in the United States alone(2). Founded with the mission to remove the fear of the unknown through powerful and accessible smNGS-based diagnostics, we have swiftly transitioned from a research and development (R&D) focused company to a proven commercial organization. In 2019, we launched our first prenatal product, UNITY. UNITY is the first non-invasive prenatal test (NIPT) that uses cfDNA to provide fetal risk assessment for recessive conditions such as sickle cell disease (SCD) and cystic fibrosis (CF) without requiring a paternal sample or invasive procedures such as amniocentesis. Since then, we have established ourselves as a leader in the prenatal testing market and expanded our UNITY offering to cover comprehensive prenatal genetic needs from a single maternal blood draw. While we know of competitors working to develop and launch competing NIPTs for recessive conditions, we believe the differentiation of our smNGS technology and five years of accumulated data and publications will allow us to maintain our competitive advantage as this type of testing becomes the standard of care and significantly improves patient outcomes(3). In the oncology setting, ultrasensitive tests with real-time insights are required to effectively detect, diagnose, and treat patients with a diverse range of mutations and solid tumor types across the cancer care continuum. In 2023, we successfully leveraged our smNGS platform to launch two complementary pan-cancer liquid biopsy tests – Northstar Select and Northstar Response. Our Northstar Select test is used to guide therapy selection and has been shown to detect over 50% more actionable solid tumor mutations than conventional liquid biopsies(4),(5). Based on our knowledge of all widely available tests, Northstar Response is the only methylation-based assay that quantifies the amount of cancer (tumor burden) at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. Our Northstar tests give physicians extraordinary visibility into cancer profile and treatment response, enabling more informed and earlier treatment decisions that can fundamentally alter patient outcomes. Our business momentum is evidenced by our rapidly scaling commercial success and improving operational efficiency. Of approximately one million smNGS-based tests that we have processed since our initial launch, over 50% of them, or approximately 508,000 tests, were processed within the last 12 months ended June 30, 2025. For the year ended December 31, 2024, we generated revenue of $152.6 million, representing 113% year-over-year growth, with a gross margin of 53% and net loss of $41.6 million. We have incurred losses since inception, including a net loss of $41.6 million and $4.2 million for the year ended December 31, 2024 and six months ended June 30, 2025, respectively, and we had an accumulated deficit of $286.4 million as of June 30, 2025. Our loss from operations for the six months ended June 30, 2024 and 2025 was $22.8 million and $3.9 million, respectively. Our business model has demonstrated improving operational leverage, which has enabled us to reach, on a non-GAAP income from operations basis, positive operating income after adjusting for stock-based compensation expense for the six months ended June 30, 2025. During this period, we generated revenue of $125.5 million, representing 82% year-over-year revenue growth as compared to the six months ended June 30, 2024, with a gross margin of 65%. This translated to a non-GAAP income from operations of $1.2 million for the six months ended June 30, 2025 compared to a non-GAAP loss from operations of $18.9 million for the six months ended June 30, 2024, which represented an improvement of approximately $20.1 million. Backed by our commitment to continued innovation and high-quality execution, we aim to lead the next wave of advancements in precision diagnostics, delivering profound benefits to patients, providers, and the broader healthcare system. (1) Our smNGS platform overcomes the technical noise that restrains the traditional NGS testing methods used by other diagnostic companies. (2) Half of this addressable market includes early detection, an area in which we have not yet begun specific product development or commercial sales, but we believe will be strongly enabled by our existing technology platform. (3) This is based on (i) our six months ended June 30, 2025 prenatal testing revenue as compared to the publicly disclosed prenatal testing revenue of Myriad Genetics, one of the largest laboratories for prenatal diagnostic testing, and (ii) recent ACOG practice advisory changes for RhD and fetal antigen NIPT have specifically cited our publications, resulting in changes to the standard of care. (4) Bower, X., Wignall, J., Varga, M. G., Zhu, J., O’Sullivan, M., Searle, N. E., Hong, L. K., Dogruluk, T., Li, Z., Farmer, T. E., Rosas-Linhard, E., Luong, J., Lin, E., Simon, M. E., Tsao, D. S., Bosch, J. R. T., Palmer, G., Gajra, A., Huynh, C., & Zhou, W. (2025). Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling. The Journal of Liquid Biopsy, 100322. (5) More than 50% more actionable/reportable mutations when compared to the comparator products in the aggregate. Actual percentages may vary depending on the individual comparator test. Our principal executive offices are located in Menlo Park, CA.

CorVel stock logo

CorVel NASDAQ:CRVL

$70.14 -1.09 (-1.53%)
Closing price 04:00 PM Eastern
Extended Trading
$70.08 -0.06 (-0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions. In addition, it provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company offers solutions to employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. CorVel Corporation was incorporated in 1987 and is based in Fort Worth, Texas.

LifeStance Health Group stock logo

LifeStance Health Group NASDAQ:LFST

$12.28 +0.12 (+0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$12.58 +0.31 (+2.48%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Omada Health stock logo

Omada Health NASDAQ:OMDA

$23.94 -0.14 (-0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$23.94 +0.00 (+0.02%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.